CN111888370A - 一种虾青素和人参皂苷Rg3联合组合物制备抗肝癌的药物 - Google Patents
一种虾青素和人参皂苷Rg3联合组合物制备抗肝癌的药物 Download PDFInfo
- Publication number
- CN111888370A CN111888370A CN202010779060.3A CN202010779060A CN111888370A CN 111888370 A CN111888370 A CN 111888370A CN 202010779060 A CN202010779060 A CN 202010779060A CN 111888370 A CN111888370 A CN 111888370A
- Authority
- CN
- China
- Prior art keywords
- astaxanthin
- ginsenoside
- liver cancer
- medicine
- combined composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 title claims abstract description 45
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 title claims abstract description 45
- 229940022405 astaxanthin Drugs 0.000 title claims abstract description 45
- 235000013793 astaxanthin Nutrition 0.000 title claims abstract description 45
- 239000001168 astaxanthin Substances 0.000 title claims abstract description 45
- 201000007270 liver cancer Diseases 0.000 title claims abstract description 41
- 208000014018 liver neoplasm Diseases 0.000 title claims abstract description 41
- RWXIFXNRCLMQCD-JBVRGBGGSA-N (20S)-ginsenoside Rg3 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RWXIFXNRCLMQCD-JBVRGBGGSA-N 0.000 title claims abstract description 39
- XIRZPICFRDZXPF-UHFFFAOYSA-N Ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CC(O)C3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O XIRZPICFRDZXPF-UHFFFAOYSA-N 0.000 title claims abstract description 36
- 239000003814 drug Substances 0.000 title claims abstract description 30
- 239000000203 mixture Substances 0.000 title claims abstract description 23
- 229930182494 ginsenoside Natural products 0.000 claims abstract description 6
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 5
- 229940089161 ginsenoside Drugs 0.000 claims abstract description 4
- 230000035755 proliferation Effects 0.000 claims abstract description 4
- 230000004614 tumor growth Effects 0.000 claims abstract description 4
- 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 claims description 6
- 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 claims description 6
- 239000003560 cancer drug Substances 0.000 claims description 4
- 238000007796 conventional method Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 abstract description 15
- 229940079593 drug Drugs 0.000 abstract description 8
- 238000002474 experimental method Methods 0.000 abstract description 5
- 238000000338 in vitro Methods 0.000 abstract description 5
- 241001465754 Metazoa Species 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 4
- 230000036541 health Effects 0.000 abstract description 3
- 238000001727 in vivo Methods 0.000 abstract description 3
- 230000005764 inhibitory process Effects 0.000 abstract description 3
- 230000009702 cancer cell proliferation Effects 0.000 abstract description 2
- 230000012010 growth Effects 0.000 abstract 1
- 231100000588 tumorigenic Toxicity 0.000 abstract 1
- 230000000381 tumorigenic effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 20
- 238000011580 nude mouse model Methods 0.000 description 8
- 241000699660 Mus musculus Species 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000208340 Araliaceae Species 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 102000000536 PPAR gamma Human genes 0.000 description 2
- 108010016731 PPAR gamma Proteins 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 229940121657 clinical drug Drugs 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 102000015735 Beta-catenin Human genes 0.000 description 1
- 108060000903 Beta-catenin Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 241000168517 Haematococcus lacustris Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 239000002138 L01XE21 - Regorafenib Substances 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- 235000003143 Panax notoginseng Nutrition 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- 210000002824 peroxisome Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 229960004836 regorafenib Drugs 0.000 description 1
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010779060.3A CN111888370A (zh) | 2020-08-05 | 2020-08-05 | 一种虾青素和人参皂苷Rg3联合组合物制备抗肝癌的药物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010779060.3A CN111888370A (zh) | 2020-08-05 | 2020-08-05 | 一种虾青素和人参皂苷Rg3联合组合物制备抗肝癌的药物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111888370A true CN111888370A (zh) | 2020-11-06 |
Family
ID=73245949
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010779060.3A Pending CN111888370A (zh) | 2020-08-05 | 2020-08-05 | 一种虾青素和人参皂苷Rg3联合组合物制备抗肝癌的药物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111888370A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113082039A (zh) * | 2021-03-30 | 2021-07-09 | 香港浸会大学深圳研究院 | 一种用于治疗索拉菲尼耐药肿瘤的组合物及其应用 |
CN115137831A (zh) * | 2022-06-22 | 2022-10-04 | 中国海洋大学 | 虾青素在制备抗血管生成药物增效剂中的应用以及一种药物组合物 |
-
2020
- 2020-08-05 CN CN202010779060.3A patent/CN111888370A/zh active Pending
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113082039A (zh) * | 2021-03-30 | 2021-07-09 | 香港浸会大学深圳研究院 | 一种用于治疗索拉菲尼耐药肿瘤的组合物及其应用 |
CN115137831A (zh) * | 2022-06-22 | 2022-10-04 | 中国海洋大学 | 虾青素在制备抗血管生成药物增效剂中的应用以及一种药物组合物 |
CN115137831B (zh) * | 2022-06-22 | 2023-08-15 | 中国海洋大学 | 虾青素在制备抗血管生成药物增效剂中的应用以及一种药物组合物 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2880500A (en) | Use of lipoic acid combination with ascorbic acid in the treatment of cancer | |
CN105769891B (zh) | 低极性稀有人参皂苷混合物及其用途 | |
CN111888370A (zh) | 一种虾青素和人参皂苷Rg3联合组合物制备抗肝癌的药物 | |
CN106659735A (zh) | 一种具有抗肿瘤增效减毒效果的药用溶液及包含其的药用组合物 | |
CN102552908B (zh) | 含青蒿素及青蒿素类衍生物和Bcl-2抑制剂的药物组合物及其应用 | |
WO2023092943A1 (zh) | 盐酸决奈达隆联合5-氟尿嘧啶在制备抗肿瘤药物中的应用 | |
JP2016102111A (ja) | 補助化療薬品とされる医薬組成物その用途 | |
CN111265536B (zh) | 包含稀有人参皂苷Rk2、CK和PPT的抗肿瘤组合物 | |
CN102441168B (zh) | 含芹菜素及芹菜素类衍生物和Bcl-2抑制剂的药物组合物及其在制备治疗癌症的药物中的应用 | |
CN104434939B (zh) | 三七皂苷r7和冬凌草甲素减毒增效抗肿瘤药物组合物及其应用 | |
KR101895418B1 (ko) | 에모딘을 포함하는 소라페니브의 암 치료 효과 증강용 조성물 | |
CN111228287A (zh) | 淫羊藿黄酮苷类化合物在制备治疗黑色素瘤的药物中的应用 | |
CN111870609A (zh) | 一种肠道菌群调节剂及其应用 | |
WO2024007583A1 (zh) | 人参皂苷联合pd-1阻断剂在制备抗头颈鳞癌药物中的应用 | |
CN106974908A (zh) | 含有hdac抑制剂和ire1抑制剂的药物组合物及用途 | |
CN108295085B (zh) | 原薯蓣皂苷在制备抗耐药性骨肉瘤药物中的应用 | |
CN103316035A (zh) | 碳酸氢钠在制备治疗肿瘤药物中的用途 | |
CN113209149A (zh) | 米托蒽醌与人参总皂苷联合用药在制备治疗胃癌药物中的应用 | |
CN109045052B (zh) | 用于治疗结肠癌的药物配方与应用 | |
KR20220067097A (ko) | ERR-α 억제제를 유효성분으로 하는 백혈병 치료용 약학 조성물 | |
CN107441076B (zh) | 一种治疗癌症的联合用药物 | |
CN111700900A (zh) | 一种天然免疫活化剂、til细胞促进剂及其应用 | |
CN110403924A (zh) | 一种治疗皮肤黑色素瘤的药物组合物及其制备方法 | |
WO2022222388A1 (zh) | L-山梨糖在制备治疗肿瘤的药物中的应用 | |
CN110876803B (zh) | 一种包含乳蛋白和油酸的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20220623 Address after: 430000 Hyundai, No. 41, Guanggu Avenue, Wuhan East Lake New Technology Development Zone, Wuhan City, Hubei Province C16, No. 03, floor 14, building 4, phase I, international design city (Wuhan area, free trade zone) (one site with multiple photos) Applicant after: Wuhan life aoyi Biotechnology Co.,Ltd. Address before: No.1037 Luoyu Road, Hongshan District, Wuhan City, Hubei Province 430000 Applicant before: Li Hua |
|
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20201106 |